There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals Inc (EYPT), Alnylam Pharma (ALNY) and Nabriva (NBRV) with bullish sentiments.
EyePoint Pharmaceuticals Inc (EYPT)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on EyePoint Pharmaceuticals Inc, with a price target of $4.50. The company’s shares closed yesterday at $1.67, close to its 52-week low of $1.24.
Selvaraju commented:
“Our 12-month price target is derived from a market value of the firm at $461M, which includes a discounted cash flow-based asset value of $511M that includes DEXYCU, YUTIQ, and royalties from RETISERT and 15% discount rate and 2% terminal growth rate, excluding $50M debt and assuming 106.1M shares outstanding at the end of 1Q20. Risks include, but are not limited to: (1) failure of YUTIQ or DEXYCU to achieve commercial success due to market size, penetration rate, and/or competition; (2) potential default risk; and (3) potential dilution risk.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.5% and a 33.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for EyePoint Pharmaceuticals Inc with a $5.25 average price target.
See today’s analyst top recommended stocks >>
Alnylam Pharma (ALNY)
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Alnylam Pharma, with a price target of $150. The company’s shares closed yesterday at $83.03.
According to TipRanks.com, Nakae has currently no stars on a ranking scale of 0-5 stars, with an average return of -15.2% and a 33.7% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and BioSig Technologies Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $128 average price target, a 54.2% upside from current levels. In a report issued on April 26, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $138 price target.
Nabriva (NBRV)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Nabriva, with a price target of $7. The company’s shares closed yesterday at $2.17.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 10.7% and a 39.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
Nabriva has an analyst consensus of Moderate Buy, with a price target consensus of $8.38, a 286.2% upside from current levels. In a report released yesterday, Northland Securities also assigned a Buy rating to the stock with a $12.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
